Recent Updates
Recently added Catalysts
KURA Positive Sentiment Score: 65/100

Kura Oncology to Report Fourth Quarter and Full Year 2022 Financial Results

Thursday, February 16, 2023 2 min read
Key Takeaway: Kura Oncology, a clinical-stage biopharmaceutical company, announced its fourth quarter and full-year financial results will be reported on February 23, 2023. The company plans to host a webcast and conference call to discuss these results and provide a corporate update. Kura's drug pipeline includes promising candidates such as ziftomenib and tipifarnib, which are being investigated for various cancer indications.

Market Sentiment Analysis

POSITIVE FACTORS

  • Kura Oncology is committed to precision medicines for cancer treatment.
  • The company has a promising pipeline of drug candidates targeting cancer signaling pathways.
  • Breakthrough Therapy Designation received for tipifarnib offers hope for patients.

Full Press Release Details

SAN DIEGO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2022 financial results after U.S. financial markets close on Thursday, February 23, 2023. Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.
To participate in the teleconference, domestic callers should dial 1-877-407-4018 and international callers should dial 1-201-689-8471. A live webcast of the call can be accessed using this weblink: https://viavid.webcasts.com/starthere.jsp?ei=1595273&tp_key=5fdc524c8f. A replay of the webcast will be available online from the investor relations section of the company website at www.kuraoncology.com.
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib, a potent and selective menin inhibitor, is currently in a registration-directed trial for patients with NPM1-mutant acute myeloid leukemia. Tipifarnib, a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI), has received Breakthrough Therapy Designation for the treatment of patients with HRAS-mutant HNSCC. Kura is conducting a Phase 1/2 trial (KURRENT-HN) of tipifarnib in combination with the PI3Kα inhibitor alpelisib to address larger genetic subsets of HNSCC patients. Kura intends to perform initial clinical evaluation with tipifarnib while in parallel advancing KO-2806, the Company’s next-generation FTI, through a Phase 1 first-in-human study. For additional information, please visit Kura’s website at www.kuraoncology.com.
Senior Vice President, Investor Relations &
Corporate Communications
pete@kuraoncology.com
Alexandra Weingarten
Senior Manager, Corporate Communications
alexandra@kuraoncology.com

Tags

farnesyl transferase inhibitor

Frequently Asked Questions

When will Kura Oncology announce their 2022 financial results?

Kura Oncology will announce their 2022 financial results on February 23, 2023.

How can I attend Kura's financial results conference call?

To join the call, domestic callers should dial 1-877-407-4018 and international callers 1-201-689-8471.

What is Ziftomenib used for?

Ziftomenib is a potent menin inhibitor in trials for NPM1-mutant acute myeloid leukemia.

What designation has Tipifarnib received?

Tipifarnib has received Breakthrough Therapy Designation for HRAS-mutant HNSCC treatment.

Where can I access the webcast of Kura's conference call?

The webcast can be accessed at https://viavid.webcasts.com/starthere.jsp?ei=1595273.

Tags: KURA Viatris Investor Conferences Healthcare Kura Oncology cancer treatment financial results clinical-stage biopharmaceutical
Last updated: Feb 16, 2023